苯甲腈,4-[(5-碘戊基)氧代]- | 147983-19-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 苯甲腈,4-[(5-碘戊基)氧代]-
• 英文名称: 4-(5-iodopentoxy) benzonitrile
• 英文别名: Benzonitrile, 4-[(5-iodopentyl)oxy]-；4-(5-iodopentoxy)benzonitrile
• CAS: 147983-19-5
• 化学式: C₁₂H₁₄INO
• 分子量: 315.154
• InChiKey: ZEVJOICPNUFZOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  33
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  苯甲腈,4-[(5-碘戊基)氧代]- 在 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 以94%的产率得到4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzonitrile
  参考文献：
  名称：

  [EN] AN IMPROVED PROCESS FOR PREPARING N-HYDROXY-4-{5- [4- (5-ISOPROPYL-2-METHYL-l, 3-THIAZOL-4-YL) -PHENOXY] -PENTOXY }-BENZAMIDINE
  [FR] METHODE AMELIOREE SERVANT A PREPARER N-HYDROXY-4{5-[4-(5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL)-PHENOXY]-PENTOXY}-BENZAMIDINE

  摘要：

  这项发明涉及一种改进的制备N-羟基-4-{5-[4-(5-异丙基-2-甲基-1,3-噻唑-4-基)苯氧基]戊氧基}苯甲酰胺的方法。

  公开号：

  WO2006004368A1
• 作为产物：
  描述：

  5-(4-cyanophenoxy)pentyl chloride 以99的产率得到苯甲腈,4-[(5-碘戊基)氧代]-
  参考文献：
  名称：

  Process for preparing N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)-phenoxy]-pentoxy}-benzamidine

  摘要：

  本发明涉及一种改进的制备N-羟基-4-{5-[4-(5-异丙基-2-甲基-1,3-噻唑-4-基)苯氧基]戊氧基}苯甲酰胺的方法。

  公开号：

  US07585979B2
• 作为试剂：
  描述：

  苯甲腈,4-[(5-碘戊基)氧代]- 、 4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenol 在 苯甲腈,4-[(5-碘戊基)氧代]- 作用下， 以94的产率得到4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzonitrile
  参考文献：
  名称：

  Process for preparing N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)-phenoxy]-pentoxy}-benzamidine

  摘要：

  本发明涉及一种改进的制备N-羟基-4-{5-[4-(5-异丙基-2-甲基-1,3-噻唑-4-基)苯氧基]戊氧基}苯甲酰胺的方法。

  公开号：

  US07585979B2

文献信息

• Arylethers, their manufacture and methods of treatment
  申请人：Ciba-Geigy

  公开号：US05246965A1

  公开（公告）日：1993-09-21

  The invention relates to the compounds of the formula ##STR1## wherein the C(.dbd.NH)--NHR group may be in tautomeric or isomeric form, and pharmaceutically acceptable salts thereof, in which: R is hydrogen or an acyl radical which is derived from an organic carbonic acid, an organic carboxylic acid, a sulfonic acid, or a carbamic acid; R.sub.1 is a substituent selected from an aliphatic hydrocarbon radical, an araliphatic hydrocarbon radical and a cycloaliphatic hydrocarbon radical; X.sub.1 and X.sub.3, independently of one another, are oxygen (--O--) or sulphur (--S--); and X.sub.2 is a divalent aliphatic hydrocarbon radical which may be interrupted by an aromatic radical; wherein the phenyl rings of formula I may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, an aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic, araliphatic or cycloaliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid; wherein aryl in the above definitions may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, an aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic, araliphatic or cycloaliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid; and wherein a cycloaliphatic hydrocarbon radical may be substituted by an aliphatic radical. The compounds are useful as selective LTB.sub.4 receptor antagonists in the treatment of conditions or syndromes in mammals which are responsive to LTB.sub.4 receptor antagonism.

  本发明涉及公式##STR1##的化合物及其药学上可接受的盐，其中：C(.dbd.NH)--NHR基团可以处于互变异构或同分异构形式，R为氢或由有机碳酸、有机羧酸、磺酸或氨基甲酸衍生的酰基基团；R.sub.1为从脂肪烃基、芳基脂肪烃基和环烷基脂肪烃基中选择的取代基；X.sub.1和X.sub.3独立地为氧（--O--）或硫（--S--）；X.sub.2为二价脂肪烃基，其可以由芳香基中断；在公式I中的苯环可以独立地进一步由卤素、三氟甲基、脂肪烃基、羟基和由脂肪烷基、芳基脂肪烷基或环烷基醇醚化的羟基或由脂肪烷基或芳基脂肪酸酯化的羟基的一个或多个取代基取代；在上述定义中的芳基可以独立地进一步由卤素、三氟甲基、脂肪烃基、羟基和由脂肪烷基、芳基脂肪烷基或环烷基醇醚化的羟基或由脂肪烷基或芳基脂肪酸酯化的羟基的一个或多个取代基取代；其中环烷基脂肪烃基可以由脂肪烃基取代。这些化合物在哺乳动物对LTB.sub.4受体拮抗作用有反应的情况或综合症的治疗中作为选择性LTB.sub.4受体拮抗剂是有用的。
• Process For Preparing N-Hydroxy-4--Benzamidine
  申请人：Lee Jin Soo

  公开号：US20080125596A1

  公开（公告）日：2008-05-29

  This invention relates to an improved method of preparing N-hydroxy-4-5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine.

  本发明涉及一种改进的制备N-羟基-4-5-[4-(5-异丙基-2-甲基-1,3-噻唑-4-基)苯氧基]戊氧基}苯甲酰胺的方法。
• Arylethers, their manufacture and use as medicament
  申请人：CIBA-GEIGY AG

  公开号：EP0518818A2

  公开（公告）日：1992-12-16

  The invention relates to the compounds of the formula and pharmaceutically acceptable salts thereof, in which : R is hydrogen or an acyl radical which is derived from an organic carbonic acid, an organic carboxylic acid, a sulfonic acid, or a carbamic acid ; R1 is a substituent selected from an aliphatic hydrocarbon radical, an araliphatic hydrocarbon radical and a cycloaliphatic hydrocarbon radical ; X1 and X3, independently of one another, are oxygen (-O-) or sulphur (-S-) ; and X2 is a divalent aliphatic hydrocarbon radical which may be interrupted by an aromatic radical ; wherein the phenyl rings of formula I may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, an aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic, araliphatic or cycloaliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid ; wherein aryl in the above definitions may be, independently of one another, further substituted by one or more substituents selected from halogen, trifluoromethyl, an aliphatic hydrocarbon radical, hydroxy, and hydroxy which is etherified by an aliphatic, araliphatic or cycloaliphatic alcohol or which is esterified by an aliphatic or araliphatic carboxylic acid ; and wherein a cycloaliphatic hydrocarbon radical may be substituted by an aliphatic radical. The compounds are useful as selective LTB-4 receptor antagonists in the treatment of conditions or syndromes in mammals which are responsive to LTB-4 receptor antagonism.

  本发明涉及如下式的化合物 及其药学上可接受的盐，其中： R 是氢或酰基，酰基来源于有机碳酸、有机羧酸、磺酸或氨基甲酸； R1 是选自脂肪烃基、脂肪烃基和环脂肪烃基的取代基； X1 和 X3 互不相关，分别为氧 (-O-) 或硫 (-S-)；以及 X2 是二价脂肪族烃基，可被芳香族基打断； 其中式 I 的苯基环可相互独立地进一步被一个或多个取代基取代，这些取代基可选 自卤素、三氟甲基、脂肪族烃基、羟基和被脂肪族、脂肪族或环脂肪族醇醚化或被脂 肪族或脂肪族羧酸酯化的羟基； 其中，上述定义中的芳基可彼此独立地进一步被一个或多个取代基取代，这些取代基选自卤素、三氟甲基、脂肪族烃基、羟基和被脂肪族、脂肪族或环脂肪族醇醚化或被脂肪族或脂肪族羧酸酯化的羟基；其中，环脂肪族烃基可被脂肪族基取代。这些化合物可作为选择性LTB-4受体拮抗剂，用于治疗哺乳动物体内对LTB-4受体拮抗剂有反应的病症或综合征。
• AN IMPROVED PROCESS FOR PREPARING N-HYDROXY-4-[5- [4- (5-ISOPROPYL-2-METHYL-l, 3-THIAZOL-4-YL) -PHENOXY] -PENTOXY]-BENZAMIDINE
  申请人：DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD.

  公开号：EP1773794A1

  公开（公告）日：2007-04-18
• EP1773794A4
  申请人：——

  公开号：EP1773794A4

  公开（公告）日：2009-09-09